Cosette reports FDA approval of EVOXAC oral solution for Sjögren’s-related dry mouth
Company / institutional announcement · Cosette Pharmaceuticals
Source published:
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Cosette announced FDA approval of EVOXAC cevimeline hydrochloride oral solution for dry-mouth symptoms in adults with Sjögren’s disease. The liquid formulation offers an alternative for patients who have difficulty swallowing capsules. Developed internally, it used an application pathway relying partly on existing capsule safety and efficacy data, with U.S. commercial availability expected by the end of 2026.
Why it may matter
Patient needs can support meaningful reformulation opportunities, while liquid products still require focused development of stability, palatability, and accurate dose measurement.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections